Study S002322

Effects of GLP-1 Receptor Agonist Treatment on Pulmonary Function and Quality of Life in Obese Patients With Chronic Obstructive Pulmonary Disease.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03466021
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: COMPLETED
Enrollment: 40
Start: 2018-01-01
Primary completion: 2020-05-31
Lead sponsor: Claus Bogh Juhl
Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Transition Dyspnea Index (TDI) [40 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021814	FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients. Dogan ADA, BMC research notes	2024	Other trial	PMID 38902794 DOI	cites ClinicalTrials.gov:NCT03466021; registry reference DERIVED:38902794
R0008744	Effects of Treatment with Liraglutide on Health-Related Quality of Life and Obstructive Sleep Apnea in People with Obesity and Chronic Obstructive Pulmonary Disease Dogan ADA, Research Square	2022	Randomized trial	DOI	cites ClinicalTrials.gov:NCT03466021